COLO B Overview
Coloplast A/S develops and markets intimate healthcare products and services worldwide.
Price History & Performance
|Historical stock prices|
|Current Share Price||kr.1,019.50|
|52 Week High||kr.855.20|
|52 Week Low||kr.1,187.00|
|1 Month Change||-6.51%|
|3 Month Change||-6.85%|
|1 Year Change||3.06%|
|3 Year Change||58.50%|
|5 Year Change||108.96%|
|Change since IPO||7,878.70%|
Recent News & Updates
Here's Why Coloplast (CPH:COLO B) Can Manage Its Debt Responsibly
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...
Do Coloplast's (CPH:COLO B) Earnings Warrant Your Attention?
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
Does This Valuation Of Coloplast A/S (CPH:COLO B) Imply Investors Are Overpaying?
How far off is Coloplast A/S ( CPH:COLO B ) from its intrinsic value? Using the most recent financial data, we'll take...
Coloplast (CPH:COLO B) Seems To Use Debt Quite Sensibly
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
|COLO B||DK Medical Equipment||DK Market|
Return vs Industry: COLO B exceeded the Danish Medical Equipment industry which returned 1.9% over the past year.
Return vs Market: COLO B underperformed the Danish Market which returned 22.6% over the past year.
|COLO B volatility|
|COLO B Beta||0.10|
Stable Share Price: COLO B is less volatile than 75% of Danish stocks over the past 3 months, typically moving +/- 3% a week.
Volatility Over Time: COLO B's weekly volatility (3%) has been stable over the past year.
About the Company
Coloplast A/S develops and markets intimate healthcare products and services worldwide. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as SpeediCath catheters that offer catheterization for both genders; Peristeen, an anal irrigation system for controlled emptying of the bowels; and Conveen Active urine bags.
Coloplast Fundamentals Summary
|COLO B fundamental statistics|
Is COLO B overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|COLO B income statement (TTM)|
|Cost of Revenue||kr.5.96b|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
Nov 01, 2021
|Earnings per share (EPS)||21.44|
|Net Profit Margin||24.11%|
How did COLO B perform over the long term?See historical performance and comparison
1.8%Current Dividend Yield
Is Coloplast undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: COLO B (DKK1019.5) is trading above our estimate of fair value (DKK981.69)
Significantly Below Fair Value: COLO B is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: COLO B's PE Ratio (47.5x) is in line with the Danish Medical Equipment industry average.
PE vs Market: COLO B is poor value based on its PE Ratio (47.5x) compared to the Danish market (16.3x).
Price to Earnings Growth Ratio
PEG Ratio: COLO B is poor value based on its PEG Ratio (5.6x)
Price to Book Ratio
PB vs Industry: COLO B is overvalued based on its PB Ratio (31.3x) compared to the DK Medical Equipment industry average (10.1x).
How is Coloplast forecast to perform in the next 1 to 3 years based on estimates from 15 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: COLO B's forecast earnings growth (8.5% per year) is above the savings rate (0.1%).
Earnings vs Market: COLO B's earnings (8.5% per year) are forecast to grow slower than the Danish market (10% per year).
High Growth Earnings: COLO B's earnings are forecast to grow, but not significantly.
Revenue vs Market: COLO B's revenue (7.8% per year) is forecast to grow faster than the Danish market (7.3% per year).
High Growth Revenue: COLO B's revenue (7.8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: COLO B's Return on Equity is forecast to be very high in 3 years time (55.6%).
How has Coloplast performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: COLO B has high quality earnings.
Growing Profit Margin: COLO B's current net profit margins (24.1%) are higher than last year (21.3%).
Past Earnings Growth Analysis
Earnings Trend: COLO B's earnings have grown by 9% per year over the past 5 years.
Accelerating Growth: COLO B's earnings growth over the past year (15.5%) exceeds its 5-year average (9% per year).
Earnings vs Industry: COLO B earnings growth over the past year (15.5%) underperformed the Medical Equipment industry 103.6%.
Return on Equity
High ROE: COLO B's Return on Equity (65.8%) is considered outstanding.
How is Coloplast's financial position?
Financial Position Analysis
Short Term Liabilities: COLO B's short term assets (DKK6.8B) do not cover its short term liabilities (DKK7.1B).
Long Term Liabilities: COLO B's short term assets (DKK6.8B) exceed its long term liabilities (DKK1.4B).
Debt to Equity History and Analysis
Debt Level: COLO B's debt to equity ratio (53.2%) is considered high.
Reducing Debt: COLO B's debt to equity ratio has increased from 20.3% to 53.2% over the past 5 years.
Debt Coverage: COLO B's debt is well covered by operating cash flow (136.4%).
Interest Coverage: COLO B's interest payments on its debt are well covered by EBIT (324.2x coverage).
What is Coloplast current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: COLO B's dividend (1.77%) is higher than the bottom 25% of dividend payers in the Danish market (1.13%).
High Dividend: COLO B's dividend (1.77%) is low compared to the top 25% of dividend payers in the Danish market (3.2%).
Stability and Growth of Payments
Stable Dividend: COLO B's dividends per share have been stable in the past 10 years.
Growing Dividend: COLO B's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: At its current payout ratio (84%), COLO B's payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: COLO B's dividends in 3 years are forecast to be covered by earnings (86% payout ratio).
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Kristian Villumsen (51 yo)
Mr. Kristian Villumsen has been Independent Director of Demant A/S since March 5, 2021. He has been the President and Chief Executive Officer of Coloplast A/S since December 4, 2018. Mr. Villumsen was an E...
CEO Compensation Analysis
Compensation vs Market: Kristian's total compensation ($USD3.10M) is about average for companies of similar size in the Danish market ($USD3.37M).
Compensation vs Earnings: Kristian's compensation has been consistent with company performance over the past year.
Experienced Management: COLO B's management team is seasoned and experienced (5 years average tenure).
Experienced Board: COLO B's board of directors are considered experienced (3.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Coloplast A/S's employee growth, exchange listings and data sources
- Name: Coloplast A/S
- Ticker: COLO B
- Exchange: CPSE
- Founded: 1954
- Industry: Health Care Supplies
- Sector: Healthcare
- Market Cap: kr.216.857b
- Shares outstanding: 212.71m
- Website: https://www.coloplast.com
Number of Employees
- Coloplast A/S
- Holtedam 1-3
- Capital Region of Denmark
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/16 17:02|
|End of Day Share Price||2021/10/15 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.